---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000065"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:22:19.781164+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Roche exercises oncology option under Recursion collaboration; triggers undisclosed fee

## Summary
- Roche exercised Validated Small Molecule Option for a Small Molecule Validation Program in a single oncology area.
- Option exercised on September 28, 2023; Roche to pay a Validated Small Molecule Option Fee per the agreement.
- This is under the Collaboration and License Agreement between Recursion, Genentech Inc., and F. Hoffmann-La Roche Ltd dated December 5, 2021.
- Fee amount not disclosed; option represents milestone in the existing partnership.

## SEC filing metadata
- accession: 0001601830-23-000065
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000065/0001601830-23-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000065/rxrx-20230928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000065
- JSON: https://secwatch.observer/filing/0001601830-23-000065.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.